September 29, 2017

Spotlight on the Opioid Litigation: A National Opioid Emergency: What Lies Ahead for the Pharmaceutical Industry?

Chicago partner David Sudzus and Chicago associate Russ Chibe authored an article for RX for the Defense titled “Spotlight on the Opioid Litigation: A National Opioid Emergency: What Lies Ahead for the Pharmaceutical Industry?” In the article, they discuss the recent move by the Trump administration to declare a national emergency in response to widespread opioid abuse in the United States.

As Dave and Russ explain, efforts to combat opioid abuse could target the pharmaceutical industry, the doctors who prescribe the drugs, or the users themselves, and there are many ways the pharmaceutical industry could be affected. It isn’t yet clear how the Trump administration will proceed, but in the meantime, Dave and Russ encourage pharmaceutical companies and their outside counsel to keep a close eye on new developments.

Read the article.

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.